- 1 Title: The burden of isolation to the individual: a comparison between isolation for
- 2 COVID-19 and for other influenza-like illnesses in Japan
- Running title: Difference in burden of isolation between COVID-19 and ILIs
- 5 Shinya Tsuzuki, MD, MSc^{1,2,3*}; Norio Ohmagari, MD, PhD^{1,3}; Philippe Beutels, PhD²
- 6 AMR Clinical Reference Center, National Center for Global Health and Medicine,
- 7 Tokyo, Japan

11

- ² Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
- ⁹ Disease Control and Prevention Center, National Center for Global Health and
- 10 Medicine, Tokyo, Japan
- *Corresponding author: Shinya Tsuzuki, MD, MSc
- 13 National Center for Global Health and Medicine
- 14 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan
- 15 Tel: +81(0)3-3202-7181
- 16 Email: stsuzuki@hosp.ncgm.go.jp

Abstract

18

At present, there is scarce evidence about how much burden the isolation of COVID-19 19 patients is. We aimed to assess the differences between COVID-19 and other influenza 20 like illnesses in disease burden brought by isolation. We conducted an online 21 22 questionnaire survey of 302 people who had COVID-19 or other influenza-like illnesses 23 (ILIs) and compared the burden of isolation due to sickness with one-to-one propensity score matching. The primary outcomes are the duration and productivity losses of 24 25 isolation, the secondary outcome is quality of life (QOL) valuation on the day of the 26 survey. Acute symptoms of outpatient COVID-19 and other ILIs lasted 17 (interquartile 27 range [IQR] 9-32) and 7 (IQR 4-10) days, respectively. The length of isolation due to 28 COVID-19 was 18 (IQR 10-33) days and that due to other ILIs was 7 (IQR 4-11) days, 29 respectively. The monetary productivity loss of isolation due to COVID-19 was 1424.3 30 (IQR 825.6-2545.5) USD and that due to other ILIs was 606.1 (IQR 297.0-1090.9) USD, 31 respectively. OOL at the time of the survey was lower in the COVID-19 group than in 32 the "other ILIs" group (0.89 and 0.96, p = 0.001). COVID-19 infection imposes a 33 substantial disease burden, even in patients with non-severe disease. This burden is larger for COVID-19 than other ILIs, mainly because the required isolation period is 34 35 longer.

Keywords: COVID-19; disease burden; Quality of life; isolation
Word count: 2038

Acknowledgment 43 44 We thank all the people who participated in our survey. 45 **Author contributions** 46 47 Shinya Tsuzuki: Conceptualization, Funding Acquisition, Data Curation, Formal 48 Analysis, Methodology, Visualization, Project Administration, Original Draft Preparation, Norio Ohmagari: Funding Acquisition, Project Administration, Supervision, 49 Review and Editing. Philippe Beutels: Conceptualization, Methodology, Supervision, 50 51 Project Administration, Review & Editing. 52 53 Data availability 54 The data that support the findings of this study are available upon request to the 55 corresponding author. The data are not publicly available due to privacy or ethical restrictions. 56 57 58 **Funding** 59 This research was funded by JSPS KAKENHI [Grant number 18K17369], a grant for 60 the National Center for Global Health and Medicine [20A05] and the Health and Labor

Sciences Research Grant, "Research for risk assessment and implementation of crisis 61 management functions for emerging and re-emerging infectious diseases". PB 62 acknowledges support from the Epipose project from the European Union's SC1-63 PHE-CORONAVIRUS-2020 programme, project number 101003688, during the 64 65 conduct of the study. 66 **Conflict of interest** 67 PB reports previous unrelated grants from Pfizer, GSK, and the European Commission 68 IMI. The other authors declare no conflicts. 69 70 71 **Ethics approval** This study was reviewed and approved by the Ethics Committee of the Center Hospital 72 73 of the NCGM (NCGM-G-004001-01). 74 75 **Patient consent** 76 Written informed consent was obtained by each participant before starting the survey 77 through an electronic form.

- 79 Permission to reproduce material from other sources
- 80 Not applicable.

Introduction 82 Coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus, has become a 83 84 global health threat [1–3]. More than half a year after the roll-out of highly effective 85 vaccines against COVOD-19, the pandemic remains difficult to control [4]. 86 COVID-19 can be regarded as one of the influenza-like illnesses (ILIs) because it causes upper respiratory symptoms like seasonal influenza and its severity is mild in 87 most cases [5-7]. However, there are several distinctive characteristics which 88 differentiate COVID-19 from other ILIs. 89 90 First, COVID-19 is more likely to result in severe illness and death than other ILIs 91 do. Previous studies suggested that the infection-fatality rate of COVID-19 was about ten times higher than that of seasonal influenza [5,8]. Although patients often recover 92 93 with only mild symptoms, COVID-19 infection should be another important cause of 94 excess death [9]. Second, the transmission dynamics of COVID-19 is quite different from other ILIs, 95 96 in that pre- and asymptomatic transmission is more common than for other ILIs [10–12]. Additionally, both incubation period and infectious period of COVID-19 were regarded 97 as longer than those of other ILIs [13,14]. These facts suggest that COVID-19 required 98 99 a longer duration of isolation as a countermeasure in order to slow down its spread. 100 Presumably, we need to strengthen our isolation policy in order to prevent further

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

spreading of COVID-19 due to the reasons mentioned above. However, at the same time, we have to consider the societal burden of such intervention including productivity loss because its appropriate duration should be determined by a kind of trade-off between disease prevention effect and societal loss. At the early stage of the pandemic, the Japanese government determined the duration of isolation for COVID-19 patients as two weeks [15], following the recommendation published by World Health Organization (WHO), Centers for Disease Control and Prevention (CDC) and other organizations [16–18]. This recommendation was updated as "10 days after symptom onset, plus at least 3 additional days without symptoms" in June 2020 [15], based on the updated recommendation published by WHO and other organizations [16–18]. However, these recommendations were defined based on clinical insights. It would be relevant to try and define the duration of isolation with both clinical, economic and societal aspects taken into consideration because such long duration of isolation may present a substantial burden for the patients. At present, there is scarce evidence about how much burden the isolation of COVID-19 patients is. The main objective of the present study is to estimate its burden from a societal perspective.

Methods

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

Settings

We conducted an online questionnaire survey of 302 people who had COVID-19 or other influenza-like illnesses (ILIs) between 1st October 2019 and 28th February 2021. The participants were voluntarily and randomly recruited from registrants of NEO MARKETING INC, a Japanese marketing research company. The participants were asked to provide information on the latest episode of isolation due to having ILIs during the study period and stratified them into (a) COVID-19 group and (b) other ILIs group. We defined ILIs as these diseases diagnosed by physicians; COVID-19, seasonal influenza, adenovirus infection, respiratory syncytial virus (RSV) infection, hand, foot and mouth disease, pertussis, and other common colds. We did not use the definition of ILI [19] because asymptomatic infection is common in COVID-19 and other ILIs, in which case not symptoms, but diagnoses provide the rationale for isolation. The responders had to be at least 20 years old. Informed consent was given before the start of the survey.

Statistical analysis

We collected data on sex, age, number of household members, education level,

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

household and individual income, duration of symptoms and isolation, and Quality of Life (QOL) at the time of questionnaire survey. As for QOL, we used the 15-D questionnaire [20] to estimate QOL value at the time the survey was conducted. Categorical variables were presented as absolute number and percentage, continuous variables as median and interquartile range (IQR). We compared the COVID-19 group with the "other ILIs" group. The primary outcome is duration and productivity loss of isolation evaluated as monetary value; the secondary outcome is QOL value. We compared the outcomes between two groups using Mann-Whitney U test with one-to-one, nearest neighbour propensity score matching (caliper = 0.2) [21]. Age, sex, education level and presence of underlying medical conditions were adjusted. Monetary value of productivity loss was calculated by multiplication of duration (days) and wage of each participant (per day equivalent). We transformed Japanese Yen (JPY) to USD as 110 JPY = 1 USD, according to the exchange rate in 2021. The QOL values were compared after excluding participants who presented any symptoms at the time of questionnaire survey. Additionally, we compared QOL values between participants who presented any symptoms due to COVID-19 and those do not. Two-sided p values of < 0.05 were considered to show statistical significance.

All analyses were conducted by R, version 4.0.5.[22]

Ethics approval

This study was approved by the Ethics Committee of National Center for Global Health

and Medicine (NCGM-G-004001-01).

160

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

Results Table 1 shows the demographic characteristics of participants. 138 were classified into COVID-19 group and 164 were other ILIs group. The basic characteristics of two groups were similar. The median duration of symptoms and isolation for other ILIs group were 7 days, while those for COVID-19 group were 15.5 and 17.0 days. (Table 1) Table 2 describes the details of data after propensity score matching. Standardized mean difference (SMD) larger than 0.1 was regarded as significant imbalance. (Table 2) Table 3 shows the outcome comparison between the COVID-19 group and the "other ILIs" group. The COVID-19 group showed longer duration of symptoms (18 days versus 7 days) and isolation (16 days versus 7 days). Productivity loss of isolation due to COVID-19 was greater than that due to other ILIs (1424.3 USD and 606.1 USD,

| 180 | respectively). The QOL value of COVID-19 group was lower than that of other ILIs |
|-----|---|
| 181 | group (0.96 and 0.89, respectively). |
| 182 | |
| 183 | (Table 3) |
| 184 | |
| 185 | Figure 1 shows the probability density curve of duration of symptoms and isolation, |
| 186 | productivity loss, and Quality of Life at the day of questionnaire survey. |
| 187 | |
| 188 | (Figure 1) |
| 189 | |
| 190 | |

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

Discussion We showed the difference between COVID-19 and other ILIs in relation to the individual QOL and economic impact of isolation. As expected, COVID-19 imposes us heavier burden on our society than other ILIs such as seasonal influenza do in various aspects. First, the longer duration of isolation brings us greater absenteeism. It is noteworthy that the median duration of isolation (16 days by the data after propensity score matching) was longer than 14 days. As described above, its duration in Japan was determined as 14 days at the early stage of the pandemic and changed to 10 days later by Ministry of Health, Labour and Welfare (MHLW) [15]. Japanese government also adopted the condition defined by WHO [16] that "plus at least 3 additional days without symptoms (including without fever and without respiratory symptoms)" then longer duration of symptoms bring us longer duration of isolation. As for other ILIs group, the most frequent diagnosis was seasonal influenza (74.4%). It was probably due to the isolation policy specific to Japan [23]. Not MHLW but Ministry of Education, Culture, Sports, Science and Technology defined the isolation period due to seasonal influenza for school children based on School Health and Safety

Act [24]. This law defines five-days isolation period for seasonal influenza with the day

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

of symptom onset as day 0. It is a main cause of comparatively long isolation period for seasonal influenza in Japan [23]. Therefore, the burden caused by isolation due to seasonal influenza in Japan seems heavier than that in other countries, nevertheless, that caused by COVID-19 imposes a heavier burden. As a result of longer duration of isolation, its productivity loss became larger in COVID-19 group than in other ILIs group. In addition, our results showed the productivity loss from patients' perspective. If we consider societal perspective, productivity losses caused by other aspects might be another burden to our society. For instance, different from other ILIs, COVID-19 patients were often isolated (in case the patients have no risk factors of severe diseases and their cohabitants have any risk factors)[15] at not their own home but some hotels. Although their accommodation fee and healthcare professional personnel costs are covered by the government, the quantitative evaluation of these costs are not available. OOL value is another point to be discussed. Even after we adjust participants' background of two groups, there were significant differences in QOL value at the day of questionnaire survey between COVID-19 group and other ILIs group (0.89 and 0.96, respectively). This result might suggest that, even if patients were not aware of its symptoms, COVID-19 had long-term effect on their health status.

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

So-called "long COVID" or "post COVID syndrome" is not fully defined [25,26], however, one of the phenomena specific to COVID-19 compared with other ILIs and it will bring us further additional burden on our society. In our survey, more than a half (70/138, 50.7%) of participants who had COVID-19 infection answered that their symptom(s) lasts more than four weeks. Conversely, only 13 out of 164 (7.9%) in other ILIs group showed the duration of symptoms longer than four weeks. The proportion of patients who reported "long COVID" varies between studies [27,28], and our result (50.7%) is not substantially different from these findings. Considering this, even after its acute phase, COVID-19 may continue to have a negative impact on QOL and productivity, more frequently and longer than for other ILIs. Our study includes several limitations. First, as our data were based on an online survey, it requires participants to have basic internet literacy. That is, participants of our survey might have more interest in their health status and better knowledge of basic computational skill than the general Japanese population do. Second, as already discussed in this section, productivity loss was evaluated only from participants' viewpoint, and no data are available about its societal perspective (accommodation fee, healthcare professional personnel, etc.). Third, QOL was assessed at the day of questionnaire survey and not assessed at the time they had symptoms due

to COVID-19 or other ILIs because 15-D questionnaire does not set any recall period.

More precise quantitative evaluation of productivity loss and health-related QOL will be a future challenge.

In conclusion, our results showed that COVID-19 imposes heavier burden on us than other ILIs do, not only its symptoms but also productivity loss due to its longer duration of isolation. These findings will be helpful for healthcare policy makers to determine the appropriate duration of isolation. "long COVID" might be a common phenomenon which bring us an additional burden, then quantitative evaluation of the burden of "long COVID" would be one of future challenges as well as more precise assessment of productivity loss and QOL value.

256 References 257 1. Guan W, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New 258 *England Journal of Medicine* 2020; **382**: 1708–1720. 259 260 2. **Huang C, et al.** Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet* 2020; **395**: 497–506. 261 3. Chen N, et al. Epidemiological and clinical characteristics of 99 cases of 2019 262 263 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 2020; **395**: 507–513. 264 265 4. WHO Coronavirus (COVID-19) Dashboard. (https://covid19.who.int). Accessed 4 July 2021. 266 5. Pastor-Barriuso R, et al. Infection fatality risk for SARS-CoV-2 in community 267 268 dwelling population of Spain: nationwide seroepidemiological study. BMJ (Clinical 269 research ed.) 2020; **371**: m4509. 6. Tian S, et al. Characteristics of COVID-19 infection in Beijing. Journal of Infection 270 271 2020; Published online: February 2020.doi:10.1016/j.jinf.2020.02.018. 272 7. Matsunaga N, et al. Clinical epidemiology of hospitalized patients with COVID-19 in Japan: Report of the COVID-19 REGISTRY JAPAN. Clinical infectious 273 diseases : an official publication of the Infectious Diseases Society of America 274 2020; Published online: September 2020.doi:10.1093/cid/ciaa1470. 275 276 8. van Asten L, et al. Excess Deaths during Influenza and Coronavirus Disease and 277 Infection-Fatality Rate for Severe Acute Respiratory Syndrome Coronavirus 2, the 278 Netherlands. *Emerging Infectious Diseases* 2021; **27**: 411–420. 279 9. Vestergaard LS, et al. Excess all-cause mortality during the COVID-19 pandemic in Europe – preliminary pooled estimates from the EuroMOMO network, March to 280 281 April 2020. Eurosurveillance European Centre for Disease Prevention and Control, 2020; **25**: 2001214. 282 283 10. **Byambasuren O, et al.** Estimating the extent of asymptomatic COVID-19 and its

- 284 potential for community transmission: Systematic review and meta-analysis.
- 285 Official Journal of the Association of Medical Microbiology and Infectious Disease
- 286 Canada University of Toronto Press, 2020; 5: 223–234.
- 287 11. **Bai Y, et al.** Presumed Asymptomatic Carrier Transmission of COVID-19. *JAMA* 2020; Published online: 21 February 2020.doi:10.1001/jama.2020.2565.
- 289 12. Ganyani T, et al. Estimating the generation interval for coronavirus disease
- (COVID-19) based on symptom onset data, March 2020. Eurosurveillance
- European Centre for Disease Prevention and Control, 2020; **25**: 2000257.
- 292 13. Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel
- coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28
- January 2020. Eurosurveillance European Centre for Disease Prevention and
- 295 Control, 2020; **25**: 2000062.
- 296 14. Chun JY, Baek G, Kim Y. Transmission onset distribution of COVID-19.
- 297 International journal of infectious diseases: IJID: official publication of the
- 298 International Society for Infectious Diseases 2020; **99**: 403–407.
- 299 15. Ministry of Health Labour and Welfare Japan. List of information for local
- 300 authorities and healthcare facilities (administrative notices, etc.) (novel coronavirus
- 301 *infections*) 2020.
- 302 (https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000121431 00212.html).
- 303 Accessed 6 July 2021.
- 304 16. World Health Organization. Criteria for releasing COVID-19 patients from
- 305 isolation.
- 306 (https://www.who.int/news-room/commentaries/detail/criteria-for-releasing-covid-1
- 9-patients-from-isolation). Accessed 6 July 2021.
- 308 17. Centers for Disease Control and Prevention. Interim Guidance on Ending
- 309 Isolation and Precautions for Adults with COVID-19. Centers for Disease Control
- 310 and Prevention.
- 311 2020(https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html).
- 312 Accessed 7 July 2021.
- 313 18. European Centre for Disease Prevention and Control. Guidance for discharge
- 314 and ending of isolation of people with COVID-19.

- 315 2020(https://www.ecdc.europa.eu/en/publications-data/covid-19-guidance-discharge
- -and-ending-isolation). Accessed 8 July 2021.
- 19. **WHO**. WHO | Revision of clinical case definitions: influenza-like illness and severe
- 318 acute respiratory infection.
- 319 (http://www.who.int/bulletin/volumes/96/2/17-194514/en/). Accessed 2 July 2019.
- 320 20. Sintonen H, National Centre for Health Program Evaluation (Australia). The
- 321 15-D measure of health-related quality of life: reliability, validity and sensitivity of
- 322 its health state descriptive system. Fairfield, Vic.: National Centre for Health
- 323 Program Evaluation, 1994.
- 324 21. Rosenbaum PR, Rubin DB. The central role of the propensity score in
- observational studies for causal effects. : 15.
- 326 22. R Core Team. R: A Language and Environment for Statistical Computing. Vienna,
- 327 Austria: R Foundation for Statistical Computing, 2018.
- 328 23. **Tsuzuki S, Yoshihara K**. The characteristics of influenza-like illness management
- in Japan. *BMC public health* 2020; **20**: 568.
- 330 24. Ministry of Education Culture Sports Science and Technology Japan. School
- Health and Safety Act. 2015; Published online: 2015.
- 332 25. UK guidelines for managing long-term effects of COVID-19 The Lancet.
- (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00847-3/fullte
- 334 xt). Accessed 17 May 2021.
- 335 26. Ayoubkhani D, et al. Post-covid syndrome in individuals admitted to hospital with
- covid-19: retrospective cohort study. *BMJ* British Medical Journal Publishing Group,
- 337 2021; **372**: n693.
- 338 27. Nalbandian A, et al. Post-acute COVID-19 syndrome. Nature Medicine 2021; 27:
- 339 **601–615**.

- 340 28. Miyazato Y, et al. Prolonged and Late-Onset Symptoms of Coronavirus Disease
- 341 2019. Open forum infectious diseases 2020; 7: ofaa507.

Table 1. Demographic characteristics of the participants

| | COVID-19 group | Other ILIs group |
|-----------------------------|-------------------|-------------------|
| Number of participants | 138 | 164 |
| Male | 97 (70.3) | 110 (67.1) |
| Age (median [IQR]) | 45.5 [37.0, 55.0] | 46.0 [36.0, 56.0] |
| Number of household members | | |
| 1 | 33 (23.9) | 35 (21.3) |
| 2 | 23 (16.7) | 29 (17.7) |
| 3 | 35 (25.4) | 49 (29.9) |
| > 4 | 47 (34.1) | 51 (31.1) |
| Diagnosis | | |
| COVID-19 | 138 (100.0) | 0 (0.0) |
| Seasonal influenza | 0 (0.0) | 122 (74.4) |
| RSV infection | 0 (0.0) | 1 (0.6) |
| Hand, foot, mouth disease | 0 (0.0) | 1 (0.6) |
| Pertussis | 0 (0.0) | 1 (0.6) |
| Common cold | 0 (0.0) | 39 (23.8) |

Comorbidities

| Asthma | 37 (26.8) | 30 (18.3) | | |
|------------------------------|-------------|------------|--|--|
| Allergic rhinorrhea | 46 (33.3) | 45 (27.4) | | |
| Atopic dermatitis | 25 (18.1) | 20 (12.2) | | |
| Neurological disorder | 11 (8.0) | 3 (1.8) | | |
| Respiratory diseases | 16 (11.6) | 5 (3.0) | | |
| Cardiovascular diseases | 17 (12.3) | 7 (4.3) | | |
| Diabetes mellitus | 23 (16.7) | 8 (4.9) | | |
| Renal diseases | 16 (11.6) | 7 (4.3) | | |
| Liver diseases | 10 (7.2) | 8 (4.9) | | |
| Metabolic diseases | 13 (9.4) | 2 (1.2) | | |
| Immunodeficiency | 14 (10.1) | 4 (2.4) | | |
| Pregnancy | 4 (2.9) | 0 (0.0) | | |
| No comorbidities | 58 (42.0) | 72 (43.9) | | |
| Place of isolation | | | | |
| Home | 86 (62.3) | 157 (95.7) | | |
| Hotel | 51 (37.0) | 12 (7.3) | | |
| Hospital | 51 (37.0) | 7 (4.3) | | |
| Duration of work restriction | 14 [10, 23] | 5 [4, 10] | | |

| 2272.7 [1818.2, 4545.5] | 2272.7 [1363.6, 3636.4] | | |
|-------------------------|--|--|--|
| 80.0 [50.0, 100.0] | 95.0 [50.0, 100.0] | | |
| Education level | | | |
| 0 (0.0) | 3 (1.8) | | |
| 22 (15.9) | 42 (25.6) | | |
| 29 (21.0) | 15 (9.2) | | |
| 71 (51.4) | 91 (55.5) | | |
| 16 (11.6) | 13 (7.9) | | |
| 0.89 [0.73, 0.97] | 0.95 [0.84, 0.99] | | |
| 15.5 [11, 25] | 7 [5, 12] | | |
| 17 [9, 32] | 7 [4, 10] | | |
| 11 (8.0) | 1 (0.6) | | |
| | 22 (15.9) 29 (21.0) 71 (51.4) 16 (11.6) 0.89 [0.73, 0.97] 15.5 [11, 25] 17 [9, 32] | | |

³⁴⁵ ILI; influenza-like illness, RSV; respiratory syncytial virus, USD; United States Dollar

348

349

Numbers with square brackets represent median value and interquartile range

 $^{(110 \}text{ Japanese Yen} = 1 \text{ USD})$

Numbers with brackets represent absolute number and percentage

Table 2. Demographic characteristics of data after propensity score matching

| | COVID-19 group | Other ILIs group | SMD | |
|---------------------------|-------------------|-------------------|-------|--|
| Number of participants | 128 | 128 | | |
| Male | 92 (71.9) | 89 (69.5) | 0.052 | |
| Age (median [IQR]) | 44.0 [37.0, 54.0] | 46.0 [36.0, 55.0] | 0.019 | |
| Diagnosis | | | | |
| COVID-19 | 128 (100.0) | 0 (0.0) | | |
| Seasonal influenza | 0 (0.0) | 94 (73.4) | | |
| RSV infection | 0 (0.0) | 1 (0.8) | | |
| Hand, foot, mouth disease | 0 (0.0) | 1 (0.8) | | |
| Pertussis | 0 (0.0) | 1 (0.8) | | |
| Common cold | 0 (0.0) | 31 (24.2) | | |
| Comorbidities | | | | |
| Asthma | 36 (28.1) | 24 (18.3) | | |
| Allergic rhinorrhea | 44 (34.4) | 38 (29.7) | | |
| Atopic dermatitis | 25 (19.5) | 15 (11.7) | | |
| Neurological disorder | 2 (1.6) | 11 (8.6) | | |
| Respiratory diseases | 15 (11.7) | 3 (2.3) | | |

| Cardiovascular diseases | 13 (10.2) | 4 (3.1) | |
|-------------------------|-----------|------------|--------|
| Diabetes mellitus | 22 (17.2) | 5 (3.9) | |
| Renal diseases | 15 (11.7) | 4 (3.1) | |
| Liver diseases | 9 (7.0) | 6 (4.7) | |
| Metabolic diseases | 12 (9.4) | 2 (1.6) | |
| Immunodeficiency | 13 (10.2) | 2 (1.6) | |
| Pregnancy | 3 (2.3) | 0 (0.0) | |
| No comorbidities | 53 (41.4) | 55 (43.0) | 0.0156 |
| Place of isolation | | | |
| Home | 79 (61.7) | 123 (96.1) | |
| Hotel | 48 (37.5) | 11 (8.6) | |
| Hospital | 47 (36.7) | 74(3.1) | |
| Education level | | | 0.019 |
| Secondary school | 0 (0.0) | 0 (0.0) | |
| High school | 27 (21.1) | 21 (16.4) | |
| Vocational school | 27 (21.1) | 12 (9.4) | |
| University | 66 (51.6) | 80 (62.5) | |
| Graduate school | 14 (10.9) | 9 (7.0) | |

- 351 ILI; influenza-like illness, SMD; standardized mean difference RSV; respiratory
- syncytial virus, USD; United States Dollar (110 Japanese Yen = 1 USD)
- Numbers with brackets represent absolute number and percentage
- Numbers with square brackets represent median value and interquartile range

Table 3. Comparison of outcomes between two groups by matched data

| | COVID-19 group | Other ILIs group | p value* |
|--------------------------|------------------------|-----------------------|----------|
| Duration of symptoms | 18 [10, 33] | 7 [4, 11] | < 0.001 |
| Duration of isolation | 16 [11, 25] | 7 [5, 12] | < 0.001 |
| Productivity loss due to | 1424.3 [825.6, 2545.5] | 606.1 [297.0, 1090.9] | < 0.001 |
| isolation (JPY) | [,] | | 0.00 |
| Quality of Life | 0.89 [0.72, 0.97] | 0.96 [0.86, 0.99] | 0.001 |

³⁵⁸ ILI; influenza-like illness, USD; United States Dollar, JPY; Japanese Yen (1 USD = 110

359 **JPY**)

362

355

356

- *Results of Mann-Whitney U test
- Numbers with square brackets represent median value and interquartile range

Figure 1. Probability density curve of duration of symptoms and isolation, productivity loss and Quality of life

Top left panel shows duration of symptoms. Top right panel shows duration of isolation.

Bottom left panel shows productivity loss. Bottom right panel shows Quality of life.

ILI; influenza-like illness, QOL; Quality of life

Red area represents COVID-19 group and Blue area represents other ILIs group.

